Strategic partnerships Leverage collaboration with Nestlé Health Science for commercialization of VOWST and explore co-development or licensing opportunities with parallel consumer health or prescription collaboration partners to expand access and distribution channels.

Clinical expansion Target institutions and networks performing allogeneic hematopoietic stem cell transplantation and GI infection care to discuss SER-155 and other microbiome candidates, positioning Seres as a partner for post-transplant infection protection programs.

Next generation Highlight ongoing preclinical and early-stage programs such as SER-603 for inflammatory bowel disease to identify partners or buyers interested in next-gen live biotherapeutics and broaden the company’s portfolio in high-need indications.

Funding signals Monitor non-dilutive funding opportunities (for example CARB-X and government grants) and propose strategic collaborations to accelerate development while preserving equity, signaling potential for co-sponsored studies and manufacturing support.

Global visibility Capitalize on recent conference participation and executive leadership changes to generate targeted outreach to investors, large pharma, and contract development/manufacturing organizations seeking partnerships in microbiome therapeutics and specialty biosciences.